Arca
Skip to content
Tools
Tools

Pyoderma

Drug research and approvals for pyoderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 4 studies of pyoderma are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 4
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 4 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

5 in phase 3, 6 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Gevokizumab
Phase 3 Interleukin-1 beta negative allosteric modulator
Adalimumab
Phase 3 TNF-alpha inhibitor
Vilobelimab
Phase 3 Complement C5 inhibitor
Oxygen
Phase 3 Essential for cellular homeostasis
Dioxydine
Phase 3
Secukinumab
Phase 2 Interleukin 17A inhibitor
Canakinumab
Phase 2 Interleukin-1 beta inhibitor
Etrasimod
Phase 2 Sphingosine 1-phosphate receptor Edg-1 agonist
Bermekimab
Phase 2 Interleukin-1 alpha inhibitor
Ixekizumab
Phase 2 Interleukin 17A inhibitor
Spesolimab
Phase 2 IL36 receptor antagonist
Cravacitinib
Early phase 1 Tyrosine-protein kinase TYK2 negative allosteric modulator

How Its Trials Ended

35 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 10 whose ending is known, 10% met their primary endpoint, 0% missed it and 90% stopped early.

  • Completed, result not reported1234%
  • Ongoing1029%
  • Stopped: other or unclear720%
  • Status unknown39%
  • Met its primary endpoint13%
  • Stopped: enrollment or feasibility13%
  • Stopped: sponsor or business decision13%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Aug 22, 2024A multi-centre, randomised, placebo-controlled, double blind, parallel-group trial to evaluate safety and efficacy of spesolimab (bi 655130) in adult patients…Spesolimab (bi 655130)Boehringer Ingelheim (Canada) Ltd LteeOngoing
Feb 12, 2019Open label exploratory phase IIa trial to investigate the safety and efficacy of ifx-1 in treating subjects with pyoderma gangrenosumIFX-1 (CACP29)Inflarx GmbHClosed
Jan 16, 2015A 2-year, open-label, safety extension study of gevokizumab in subjects with pyoderma gangrenosumGevokizumabXoma US LLCOngoing
Jan 16, 2015A randomized, double-blind, placebo-controlled study of the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosumGevokizumabXoma US LLCOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Nov 9, 2025InfliximabTreatment of pyoderma gangrenosumOddifact SASDesignated
Apr 16, 2025Spesolimab-sbzoTreatment of pyoderma gangrenosumLEO Pharma Inc.Designated
Jun 27, 2022VilobelimabTreatment of pyoderma gangrenosumInflaRx N.V.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.